Repurposing Ivacaftor for treatment of Staphylococcus aureus infections

Int J Antimicrob Agents. 2017 Sep;50(3):389-392. doi: 10.1016/j.ijantimicag.2017.03.020. Epub 2017 Jul 8.

Abstract

Drug repurposing of non-antimicrobials is a novel method to augment a seriously depleted drug pipeline for targeting drug-resistant pathogens. This article highlights the potent antimicrobial activity of Ivacaftor against Staphylococcus aureus, including vancomycin- and other multidrug-resistant strains. The potent activity of Ivacaftor in vivo is also demonstrated in a murine neutropenic thigh infection model. Taken together, these results support the potential of Ivacaftor as an antimicrobial agent for the treatment of staphylococcal infections.

Keywords: Antibiotics; Drug-repurposing; Ivacaftor; MRSA.

MeSH terms

  • Aminophenols / administration & dosage*
  • Aminophenols / pharmacology
  • Animals
  • Anti-Bacterial Agents / administration & dosage*
  • Anti-Bacterial Agents / pharmacology
  • Chloride Channel Agonists / administration & dosage*
  • Chloride Channel Agonists / pharmacology
  • Disease Models, Animal
  • Drug Repositioning*
  • Mice, Inbred BALB C
  • Quinolones / administration & dosage*
  • Quinolones / pharmacology
  • Staphylococcal Infections / drug therapy*
  • Staphylococcus aureus / drug effects*
  • Treatment Outcome

Substances

  • Aminophenols
  • Anti-Bacterial Agents
  • Chloride Channel Agonists
  • Quinolones
  • ivacaftor